Non-Randall Glomerulonephritis with Non-Organized Monoclonal Ig Deposits

  • Pierre RoncoEmail author
  • Alexandre Karras
  • Emmanuelle Plaisier
Part of the Current Clinical Pathology book series (CCPATH)


Plasma cell dyscrasias can induce a variety of kidney diseases either with organized deposits - AL amyloidosis, type-1 cryoglobulin, and immunotactoid glomerulonephritis, or with non-organized deposits of light or heavy chains characteristic of LCDD and HCDD, respectively. In addition to these well-defined diseases, a recently described entity has emerged, characterized by non-Randall-type, non-organized glomerular deposition of complete IgG. The term proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID) was proposed, as most of the cases reported in the initial series shared pathologic features with membranoproliferative glomerulonephritis (MPGN). Nevertheless, cellular proliferation is sometimes minimal and the glomerulopathy can then be categorized as atypical membranous nephropathy (MN). Diagnosis relies on immunofluorescence examination demonstrating light chain isotype restriction, mostly kappa (70–80 %), associated with gamma heavy chain subclass restriction, and on electron microscopy showing lack of organization of the granular electron-dense deposits. Interestingly, the IgG subclass seems to influence the glomerular pattern as most MPGN are associated with IgG3, while the majority of MN is associated with IgG1. Less than a third of all patients have evidence of dysproteinemia by serum and urine examination, while hypocomplementemia is observed in 30 % of them, despite negative testing for cryoglobulin. Renal prognosis is poor, leading to dialysis in 20 % of cases, although it can be improved by treatment of the underlying hemopathy which should be carefully searched for. Several reports suggest that rituximab, a B-cell depleting agent, could be a promising treatment in patients without overt malignancy, including those with post-kidney transplant recurrence of the disease. Several cases of GN with isolated renal C3 deposits and circulating monoclonal gammopathy have been recently reported. These cases might represent an unusual complication of plasma cell dyscrasia, related to complement activation through an autoantibody activity of the monoclonal Ig against a complement alternative pathway regulator protein such as complement factor H.


Membranoproliferative glomerulonephritis Monoclonal component Membranous nephropathy Anti-CD20 antibody Ig subclass 


  1. 1.
    Glenner GG, Terry W, Harada M, et al. Amyloid fibril proteins: proof of homology with immunoglobulin light chains by sequence analyses. Science. 1971;172:1150–1.CrossRefPubMedGoogle Scholar
  2. 2.
    Randall RE, Williamson Jr WC, Mullinax F, et al. Manifestations of systemic light chain deposition. Am J Med. 1976;60:293–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Ivanyi B. Frequency of light chain deposition nephropathy relative to renal amyloidosis and Bence Jones cast nephropathy in a necropsy study of patients with myeloma. Arch Pathol Lab Med. 1990;114:986–7.PubMedGoogle Scholar
  4. 4.
    Karras A, Noel LH, Droz D, et al. Renal involvement in monoclonal (type I) cryoglobulinemia: two cases associated with IgG3 kappa cryoglobulin. Am J Kidney Dis. 2002;40:1091–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Lin J, Markowitz GS, Valeri AM, et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol. 2001;12:1482–92.PubMedGoogle Scholar
  6. 6.
    Bridoux F, Hugue V, Coldefy O, et al. Fibrillary glomerulonephritis and immunotactoid (microtubular) glomerulopathy are associated with distinct immunologic features. Kidney Int. 2002;62:1764–75.CrossRefPubMedGoogle Scholar
  7. 7.
    Rosenstock JL, Markowitz GS, Valeri AM, et al. Fibrillary and immunotactoid glomerulonephritis: distinct entities with different clinical and pathologic features. Kidney Int. 2003;63:1450–61.CrossRefPubMedGoogle Scholar
  8. 8.
    Nasr SH, Valeri AM, Cornell LD, et al. Fibrillary glomerulonephritis: a report of 66 cases from a single institution. Clin J Am Soc Nephrol. 2011;6:775–84.PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Nasr SH, Colvin R, Markowitz GS. IgG1 lambda light and heavy chain renal amyloidosis. Kidney Int. 2006;70:7.CrossRefPubMedGoogle Scholar
  10. 10.
    Audard V, Georges B, Vanhille P, et al. Renal lesions associated with IgM-secreting monoclonal proliferations: revisiting the disease spectrum. Clin J Am Soc Nephrol. 2008;3:1339–49.PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Alpers CE, Tu WH, Hopper Jr J, Biava CG. Single light chain subclass (kappa chain) immunoglobulin deposition in glomerulonephritis. Hum Pathol. 1985;16:294–304.CrossRefPubMedGoogle Scholar
  12. 12.
    Touchard G. Ultrastructural pattern and classification of renal monoclonal immunoglobulin deposits. In: Touchard G, Aucouturier P, Hermine O, Ronco P, editors. Monoclonal gammopathies and the kidney. Dordrecht: Kluwer; 2003. p. 95–117.CrossRefGoogle Scholar
  13. 13.
    Bridoux F, Zanetta G, Vanhille P, Goujon JM, Vanhille P, Bauwens M, Chevet D, Ronco P, Preud’homme JL, Touchard G. Glomerulopathy with non-organized and non-Randall type monoclonal immunoglobulin deposits: a rare entity [abstract]. J Am Soc Nephrol. 2001;12:94A.Google Scholar
  14. 14.
    Jokiranta TS, Solomon A, Pangburn MK, et al. Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H. J Immunol. 1999;15(163):4590–6.Google Scholar
  15. 15.
    Nasr SH, Markowitz GS, Stokes MB, et al. Proliferative glomerulonephritis with monoclonal IgG deposits: a distinct entity mimicking immune-complex glomerulonephritis. Kidney Int. 2004;65:85–96.CrossRefPubMedGoogle Scholar
  16. 16.
    Nasr SH, Satoskar A, Markowitz GS, et al. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol. 2009;20:2055–64.PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Guiard E, Karras A, Plaisier E, et al. Patterns of non-cryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab. Clin J Am Soc Nephrol. 2011;6:1609–16.CrossRefPubMedGoogle Scholar
  18. 18.
    Evans DJ, Macanovic M, Dunn MJ, et al. Membranous glomerulonephritis associated with follicular B-cell lymphoma and subepithelial deposition of IgG1-kappa paraprotein. Nephron Clin Pract. 2003;93:c112.CrossRefPubMedGoogle Scholar
  19. 19.
    Komatsuda A, Masai R, Ohtani H, et al. Monoclonal immunoglobulin deposition disease associated with membranous features. Nephrol Dial Transplant. 2008;23:3888–94.CrossRefPubMedGoogle Scholar
  20. 20.
    Masai R, Wakui H, Komatsuda A, Togashi M, Maki N, Ohtani H, Oyama Y, Sawada K. Characteristics of proliferative glomerulonephritis with monoclonal IgG deposits associated with membranoproliferative features. Clin Nephrol. 2009;72:46–54.CrossRefPubMedGoogle Scholar
  21. 21.
    Fujiwara T, Komatsuda A, Ohtani H, Togashi M, Sawada K, Wakui H. Proliferative glomerulonephritis with monoclonal IgG deposits in a patient with autoimmune hemolytic anemia. Clin Nephrol. 2013;79(6):494–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Fujita E, Shimizu A, Kaneko T, Masuda Y, Ishihara C, Mii A, Higo S, Kajimoto Y, Kanzaki G, Nagasaka S, Iino Y, Katayama Y, Fukuda Y. Proliferative glomerulonephritis with monoclonal immunoglobulin G3κ deposits in association with parvovirus B19 infection. Hum Pathol. 2012;43(12):2326–33.CrossRefPubMedGoogle Scholar
  23. 23.
    Yahata M, Nakaya I, Takahashi S, Sakuma T, Sato H, Soma J. Proliferative glomerulonephritis with monoclonal IgM deposits without Waldenström’s macroglobulinemia: case report and review of the literature. Clin Nephrol. 2012;77(3):254–60.CrossRefPubMedGoogle Scholar
  24. 24.
    Aucouturier P, Preud’Homme JL. Subclass distribution of human myeloma proteins as determined with monoclonal antibodies. Immunol Lett. 1987;16:55–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Nasr SH, Sethi S, Cornell LD, Fidler ME, Boelkins M, Fervenza FC, Cosio FG, D’Agati VD. Proliferative glomerulonephritis with monoclonal IgG deposits recurs in the allograft. Clin J Am Soc Nephrol. 2011;6(1):122–32.PubMedCentralCrossRefPubMedGoogle Scholar
  26. 26.
    Albawardi A, Satoskar A, Von Visger J, Brodsky S, Nadasdy G, Nadasdy T. Proliferative glomerulonephritis with monoclonal IgG deposits recurs or may develop de novo in kidney allografts. Am J Kidney Dis. 2011;58(2):276–81.CrossRefPubMedGoogle Scholar
  27. 27.
    Sumida K, Ubara Y, Marui Y, Nakamura M, Takaichi K, Tomikawa S, Fujii T, Ohashi K. Recurrent proliferative glomerulonephritis with monoclonal IgG deposits of IgG2lambda subtype in a transplanted kidney: a case report. Am J Kidney Dis. 2013;62(3):587–90.CrossRefPubMedGoogle Scholar
  28. 28.
    Batal I, Bijol V, Schlossman RL, Rennke HG. Proliferative glomerulonephritis with monoclonal immunoglobulin deposits in a kidney allograft. Am J Kidney Dis. 2014;63(2):318–23.CrossRefPubMedGoogle Scholar
  29. 29.
    Capra JD, Kunkel HG. Aggregation of gamma-G3 proteins: relevance to the hyperviscosity syndrome. J Clin Invest. 1970;49:610–21.PubMedCentralCrossRefPubMedGoogle Scholar
  30. 30.
    Abdelmoula M, Spertini F, Shibata T, Gyotoku Y, Luzuy S, Lambert PH, Izui S. IgG3 is the major source of cryoglobulins in mice. J Immunol. 1989;143:526–32.PubMedGoogle Scholar
  31. 31.
    Aucouturier P, Bremard-Oury C, Clauvel JP, Debré M, Griscelli C, Seligmann M, Preud’homme JL. Serum IgG subclass levels in primary and acquired immunodeficiency. Monogr Allergy. 1986;20:62–74.PubMedGoogle Scholar
  32. 32.
    Moulin B, Ronco PM, Mougenot B, Francois A, Fillastre JP, Mignon F. Glomerulonephritis in chronic lymphocytic leukemia and related B-cell lymphomas. Kidney Int. 1992;42:127–35.CrossRefPubMedGoogle Scholar
  33. 33.
    de Seigneux S, Bindi P, Debiec H, Alyanakian MA, Aymard B, Callard P, Ronco P, Aucouturier P. Immunoglobulin deposition disease with a membranous pattern and a circulating monoclonal immunoglobulin G with charge-dependent aggregation properties. Am J Kidney Dis. 2010;56:117–21.CrossRefPubMedGoogle Scholar
  34. 34.
    Oliveira DB. Membranous nephropathy: an IgG4-mediated disease. Lancet. 1998;351:670–1.CrossRefPubMedGoogle Scholar
  35. 35.
    Aucouturier P, Mounir S, Preud’homme JL. Distribution of IgG subclass levels in normal adult sera as determined by a competitive enzyme immunoassay using monoclonal antibodies. Diagn Immunol. 1985;3:191–6.PubMedGoogle Scholar
  36. 36.
    Ronco P, Debiec H. Advances in membranous nephropathy: success stories of a long journey. Clin Exp Pharmacol Physiol. 2011;38:410–6.CrossRefGoogle Scholar
  37. 37.
    Debiec H, Hanoy M, Francois A, Guerrot D, Ferlicot S, Johanet C, Aucouturier P, Godin M, Ronco P. Recurrent membranous nephropathy in an allograft caused by IgG3k targeting the PLA2 receptor. J Am Soc Nephrol. 2012;23(12):1949–54.PubMedCentralCrossRefPubMedGoogle Scholar
  38. 38.
    Bridoux F, Desport E, Frémeaux-Bacchi V, Chong CF, Gombert JM, Lacombe C, Quellard N, Touchard G. Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association? Clin J Am Soc Nephrol. 2011;6:2165–74.PubMedCentralCrossRefPubMedGoogle Scholar
  39. 39.
    Sethi S, Sukov WR, Zhang Y, Fervenza FC, Lager DJ, Miller DV, Cornell LD, Krishnan SG, Smith RJ. Dense deposit disease associated with monoclonal gammopathy of undetermined significance. Am J Kidney Dis. 2010;56:977–82.PubMedCentralCrossRefPubMedGoogle Scholar
  40. 40.
    Sethi S, Zand L, Leung N, Smith RJ, Jevremonic D, Herrmann SS, Fervenza FC. Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy. Clin J Am Soc Nephrol. 2010;5:770–82.PubMedCentralCrossRefPubMedGoogle Scholar
  41. 41.
    Leung N, Bridoux F, Hutchison CA, Nasr SH, Cockwell P, Fermand JP, Dispenzieri A, Song KW, Kyle RA, International Kidney and Monoclonal Gammopathy Research Group. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood. 2012;120(22):4292–5.CrossRefPubMedGoogle Scholar
  42. 42.
    Fermand JP, Bridoux F, Kyle RA, Kastritis E, Weiss BM, Cook MA, Drayson MT, Dispenzieri A, Leung N, International Kidney and Monoclonal Gammopathy Research Group. How I treat monoclonal gammopathy of renal significance (MGRS). Blood. 2013;122(22):3583–90.CrossRefPubMedGoogle Scholar
  43. 43.
    Bhat P, Weiss S, Appel GB, Radhakrishnan J. Rituximab treatment of dysproteinemias affecting the kidney: a review of three cases. Am J Kidney Dis. 2007;50:641–4.CrossRefPubMedGoogle Scholar
  44. 44.
    Vilayur E, Trevillian P, Walsh M. Monoclonal gammopathy and glomerulopathy associated with chronic lymphocytic leukemia. Nat Clin Pract Nephrol. 2009;5:54–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  • Pierre Ronco
    • 1
    • 2
    • 3
    Email author
  • Alexandre Karras
    • 4
  • Emmanuelle Plaisier
    • 1
    • 2
  1. 1.Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1155ParisFrance
  2. 2.Department of Nephrology and DialysisAP-HP, Hôpital TenonParisFrance
  3. 3.UMR_S 1155, Batiment Recherche, Hôpital TenonParisFrance
  4. 4.Department of NephrologyAP-HP, University Paris Descartes, Hôpital Européen Georges PompidouParisFrance

Personalised recommendations